Sponsor:
M.D. Anderson Cancer Center
Code:
NCT07700212
Conditions
Metastatic Pancreatic Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Transcutaneous LFVB (tLFVB)
Brief summary:
Conditions
Metastatic Pancreatic Adenocarcinoma
Study ID
NCT07700212
Start date
Sep 25, 2026
Status verified date
Nov, 2026
Completion date
Dec 30, 2028
Anticipated
Primary completion date
Dec 30, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
10 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Treatment with OnVagus device
Interventions
Transcutaneous LFVB (tLFVB)
Primary outcome measure
Central contacts
Locations
UT MD Anderson
Recruiting
Houston, Texas, United States, 77030
Contacts
Principal Investigator:
Brandon G. Smaglo, MD
Sponsor
M.D. Anderson Cancer Center
Last update posted
Nov 19, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.